<DOC>
	<DOC>NCT02112110</DOC>
	<brief_summary>The purpose of this study is to determine the absolute bioavailability of 150 mg oral dose of BMS-791325 relative to 100 µg IV infusion of [13C]-BMS-791325.</brief_summary>
	<brief_title>Absolute Bioavailability of BMS-791325</brief_title>
	<detailed_description>Primary Purpose: Other: Protocol is designed to assess the absolute bioavailability of 150 mg (2x75 mg tablets) BMS-791325 administered orally</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com 1. Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations 2. Men and women ages 18 to 49 years, inclusive 3. Women of childbearing potential (WOCBP) must not be pregnant or breastfeeding WOCBP and men who are sexually active with WOCBP must agree to follow protocol mandated instructions for method(s) of contraception during and after the study 1. Any significant acute or chronic medical illness 2. Any current or recent gastrointestinal disease or surgery that could impact upon the absorption of study drug 3. Inability to tolerate oral medication 4. Inability to be venipunctured and/or tolerate venous access 5. Use of tobaccocontaining or nicotinecontaining products within 6 months 6. Recent (within 6 months of study drug administration) drug or alcohol abuse as defined in Diagnostic and Statistical Manual of Mental Disorders (4th Edition)(DSM IV), Diagnostic Criteria for Drug and Alcohol Abuse 7. Any of the following on 12lead electrocardiogram (ECG) prior to study drug administration at screening or Day 1, confirmed by repeat i)PR ≥ 210 msec ii)QRS ≥ 120 msec iii)QT ≥ 500 msec iv)QTcF ≥ 450 msec v)Second or third degree heart block h) Positive urine screen for drugs of abuse i) Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, r HIV1, 2 antibodies j) Any of the following screening or Day 1 laboratory results outside the ranges specified below as defined by the laboratory, confirmed by repeat analysis: i)Serum creatinine &gt; upper limit of normal (ULN) ii)Alanine aminotransferase (ALT) &gt; ULN iii)Aspartate aminotransferase(AST) &gt; ULN iv)Total bilirubin &gt; ULN k) History of any significant drug allergy (such as anaphylaxis or hepatotoxicity)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>